Delivery Order SPE2DB20D3101-SPE2DB25FQUN2

Award Date 11/12/24
Potential Completion Date 11/13/24
Potential Value $2.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of 4,559,406,389 units of Naloxone HCl 4 mg Nasal Spray to the Defense Logistics Agency (DLA). The award, valued at $3,854.16, was made to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order with a period of performance through December 19, 2022. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,560,983,291 units of Naloxone HCL 4 mg Nasal Spray. The delivery order, valued at $1,845.84, has a firm fixed-price and is expected to be completed by May 19, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company, Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,194.32 Firm Fixed Price delivery order covers the supply of 4,561,769,383 units of Naloxone HCl 4 mg Nasal Spray, with an ultimate completion date of August 11, 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,565,367,200 units of Naloxone HCL 4 mg Nasal Spray. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $1,950.71 and an ultimate completion date of August 7, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
This federal contract award from the Defense Logistics Agency (DLA) was issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,562,626,256 units of Naloxone HCl 4 mg Nasal Spray. The firm-fixed-price delivery order, valued at $2,906.88, has an ultimate completion date of October 30, 2023. Amerisourcebergen maintains a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,535,573 units of Naloxone HCl 4 mg nasal spray. The delivery order, valued at $1,432.12, has a completion date of February 5, 2024. Amerisourcebergen Drug Corp serves as the prime contractor on an indefinite delivery contract (IDC) with DLA Troop Support Medical, with a potential value of...
This federal contract award, issued by the Defense Logistics Agency (DLA), is for the delivery of 4,560,315,275 units of Naloxone HCL 4 mg Nasal Spray. The $2,556.39 firm fixed-price contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of March 21, 2023 and is not designated as a set-aside requirement. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of 4,565,153,966 units of Naloxone HCL 4 mg Nasal Spray. The contract has a ceiling value of $1,286.36 and a completion date of July 16, 2024. It was awarded on July 15, 2024 by the Medical Supply Chain, a component of the Defense Logistics Agency (DLA) Troop Support. This is a delivery order contract with a firm fixed price pricing type. The award does not have a set-aside designation....
This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is a delivery order valued at $7,431.79 for the supply of 4,559,121,146 units of 4 mg naloxone hydrochloride nasal spray. The award was made by the Defense Logistics Agency (DLA), a defense agency, and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,557,932,236 units of Naloxone HCL 4 mg Nasal Spray. The $3,078.00 firm fixed-price delivery order has a completion date of July 29, 2022 and is not designated as a set-aside contract. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
  • SPE2DB20D3101
    Indefinite Delivery Contract
  • SPE2DB20D3101-SPE2DB25FQUN2
    Delivery Order

This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical for the delivery of 4,566,401 units of Naloxone HCl 4 mg Nasal Spray. The firm-fixed-price delivery order, valued at $2,157.33, has a completion date of November 13, 2024.

Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 2/27/25, 11:06 AM